A Multicenter, Open-Label Safety Study of Natalizumab administered to Subjects with Relapsing Forms of Multiple Sclerosis who participated in STRATA

First published 28/03/2019

Last updated 02/07/2024

EU PAS number:

EUPAS28992

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

BEL-TYS-14-10675_Tysabri_Protocol_11Aug14_final6811801528117131664_Redacted

English (2.35 MB - PDF)View document

Study results

Study results

BEL-TYS-14-10675_CSR Synopsis_10 Aug 2020

English (400.95 KB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents